Researchers report that biosimilar use was not influenced by disease type but correlated with treatment sequence, shorter ...
The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US.
A recent study confirms the stability of XSB-001 biosimilar for retinal diseases under realistic clinical handling conditions ...
A review of the safety of biosimilar DMARDs during pregnancy reveals critical evidence gaps and the need for informed clinical guidance.
The latest advancements in global biosimilar access include new treatments, strategic partnerships, and competitive market ...
To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the ...
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost ...
Patients with non-small cell lung cancer (NSCLC) taking bevacizumab biosimilars demonstrated equivalent therapeutic efficacy and similar safety profiles to those taking the originator product, Avastin ...
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara (ustekinumab), one of the most profitable drugs in the world. After Wezlana ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback